BRAF-mutations in non-small cell lung cancer

被引：63
|
作者：
Brustugun, Odd Terje [1 ,2 ]
Khattak, Asma Malik [3 ]
Tromborg, Anette Kjoshagen [3 ]
Beigi, Marzieh [3 ]
Beiske, Klaus [3 ]
Lund-Iversen, Marius [3 ]
Helland, Aslaug [1 ,2 ]
机构：
[1] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Oncol, N-0310 Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
[3] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Pathol, N-0310 Oslo, Norway
来源：
LUNG CANCER | 2014年 / 84卷 / 01期
关键词：
EGFR-mutation; BRAF-mutation; Genetic testing; Lung cancer; Tyrosine kinase inhibitors; ADENOCARCINOMAS; FEATURES; PATIENT;
D O I：
10.1016/j.lungcan.2014.01.023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objectives: Targeted therapies in non-small cell lung cancer (NSCLC) now also include inhibitors against mutated BRAF. We present clinicopathological characteristics of nearly one thousand unselected NSCLC patients tested for the targetable V600E/K BRAF-mutation. Material and methods: NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 were tested for V600E/K BRAF-mutations using a PCR-based method. Results: We found a BRAF-mutation frequency of 1.7% in the total cohort of 979 patients, and 23% among 646 adenocarcinomas. One of the BRAF-positive samples was also KRAS-mutated, and one had an ALK-translocation. None of 231 squamous cell carcinomas were BRAF-mutated. The proportion of never-smokers among BRAF-positives was high (29%). Conclusion: BRAF-mutation analysis should be part of the subtyping of non-squamous NSCLC. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：36 / 38
页数：3
相关论文
共 50 条
  • [21] Understanding BRAF mutation in non-small cell lung cancer patients
    Tine, Mariaenrica
    Squarzoni, Giulia
    Ortolan, Davide
    Pezzuto, Federica
    Calabrese, Fiorella
    Squarzoni, Giulia
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [22] Pathways and targeting avenues of BRAF in non-small cell lung cancer
    Imyanitov, Evgeny N.
    Mitiushkina, Natalia V.
    Kuligina, Ekatherina Sh.
    Tiurin, Vladislav I.
    Venina, Aigul R.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2024, 28 (07) : 613 - 622
  • [23] Germline mutations predisposing to non-small cell lung cancer
    Gerald H. Clamon
    Aaron D. Bossler
    Taher Abu Hejleh
    Muhammad Furqan
    Familial Cancer, 2015, 14 : 463 - 469
  • [24] Germline mutations predisposing to non-small cell lung cancer
    Clamon, Gerald H.
    Bossler, Aaron D.
    Abu Hejleh, Taher
    Furqan, Muhammad
    FAMILIAL CANCER, 2015, 14 (03) : 463 - 469
  • [25] Targeting driver mutations in non-small cell lung cancer
    Vreka, Malamati
    Stathopoulos, Georgios T.
    Marazioti, Antonia
    PNEUMON, 2015, 28 (02) : 130 - 132
  • [26] Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study
    Tan, Irena
    Stinchcombe, Thomas E.
    Ready, Neal E.
    Crawford, Jeffrey
    Datto, Michael B.
    Nagy, Rebecca J.
    Lanman, Richard B.
    Gu, Lin
    Clarke, Jeffrey M.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 258 - 267
  • [27] Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: A single institution, retrospective cohort study
    Tan, Irena
    Stinchcombe, Tom
    Ready, Neal E.
    Datto, Michael B.
    Nagy, Rebecca J.
    Gu, Lin
    Clarke, Jeffrey Melson
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
    Puri, Megha
    Gawri, Kunal
    Dawar, Richa
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Clinicopathological and Molecular Characteristics of Non-Small Cell Lung Cancer with BRAF Mutation
    Wang, Yue
    Li, Yuan
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1965 - S1967
  • [30] Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
    Joshi, Monika
    Rice, Shawn J.
    Liu, Xin
    Miller, Bruce
    Belani, Chandra P.
    PLOS ONE, 2015, 10 (02):
12345